DexCom Statistics

Total Valuation

DexCom has a market cap or net worth of GBP 25.24 billion. The enterprise value is 25.15 billion.

Market Cap	25.24B
Enterprise Value	25.15B

Important Dates

The last earnings date was Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	390.77M
Shares Outstanding	n/a
Shares Change (YoY)	-3.45%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	389.26M

Valuation Ratios

The trailing PE ratio is 60.94 and the forward PE ratio is 38.07.

PE Ratio	60.94
Forward PE	38.07
PS Ratio	7.86
PB Ratio	14.39
P/TBV Ratio	15.18
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 37.20, with an EV/FCF ratio of 56.50.

EV / Earnings	60.73
EV / Sales	8.01
EV / EBITDA	37.20
EV / EBIT	52.53
EV / FCF	56.50

Financial Position

The company has a current ratio of 1.50, with a Debt / Equity ratio of 1.14.

Current Ratio	1.50
Quick Ratio	1.27
Debt / Equity	1.14
Debt / EBITDA	2.89
Debt / FCF	4.49
Interest Coverage	33.12

Financial Efficiency

Return on equity (ROE) is 23.72% and return on invested capital (ROIC) is 8.16%.

Return on Equity (ROE)	23.72%
Return on Assets (ROA)	5.98%
Return on Invested Capital (ROIC)	8.16%
Return on Capital Employed (ROCE)	17.03%
Revenue Per Employee	313,221
Profits Per Employee	40,414
Employee Count	10,300
Asset Turnover	0.63
Inventory Turnover	2.90

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.74% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-43.74%
50-Day Moving Average	80.14
200-Day Moving Average	88.19
Relative Strength Index (RSI)	36.00
Average Volume (20 Days)	2,647

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.45

Income Statement

In the last 12 months, DexCom had revenue of GBP 3.21 billion and earned 414.24 million in profits. Earnings per share was 1.03.

Revenue	3.21B
Gross Profit	1.91B
Operating Income	489.63M
Pretax Income	565.63M
Net Income	414.24M
EBITDA	663.93M
EBIT	489.63M
Earnings Per Share (EPS)	1.03

Full Income Statement

Balance Sheet

The company has 2.09 billion in cash and 2.00 billion in debt, giving a net cash position of 91.49 million.

Cash & Cash Equivalents	2.09B
Total Debt	2.00B
Net Cash	91.49M
Net Cash Per Share	n/a
Equity (Book Value)	1.75B
Book Value Per Share	4.47
Working Capital	1.17B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 746.20 million and capital expenditures -301.00 million, giving a free cash flow of 445.20 million.

Operating Cash Flow	746.20M
Capital Expenditures	-301.00M
Free Cash Flow	445.20M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.43%, with operating and profit margins of 15.25% and 12.90%.

Gross Margin	59.43%
Operating Margin	15.25%
Pretax Margin	17.62%
Profit Margin	12.90%
EBITDA Margin	20.68%
EBIT Margin	15.25%
FCF Margin	13.87%

Dividends & Yields

DexCom does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.45%
Shareholder Yield	3.45%
Earnings Yield	1.64%
FCF Yield	1.76%

Stock Splits

The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.

Last Split Date	Jun 13, 2022
Split Type	Forward
Split Ratio	4

Scores

DexCom has an Altman Z-Score of 6.35.

Altman Z-Score	6.35
Piotroski F-Score	n/a